



The 65th ASH Annual Meeting Abstracts

ORAL ABSTRACTS

642. CHRONIC LYMPHOCYTIC LEUKEMIA: CLINICAL AND EPIDEMIOLOGICAL

Genetic markers and ibrutinib vs placebo treatment in early stage chronic lymphocytic leukemia -results from the GCLLSG CLL12 trial

Armin Riecke^{1,2}, Eugen Tausch, MD³, Deyan Y. Yosifov, PhD⁴, Christof Schneider, MD⁵, Sandra Robrecht, PhD⁶, Adam Giza⁶, Lothar Müller⁷, Ursula Vehling-Kaiser, MD⁸, Michael J. Eckart, MD⁹, Werner Freier¹⁰, Björn Schöttker¹¹, Tobias Gaska, MD¹², Marcel Reiser¹³, Anna-Maria Fink, MD⁶, Barbara F. Eichhorst, MD¹⁴, Kirsten Fischer, MD⁶, Michael Hallek, MD¹⁵, Petra Langerbeins⁶, Stephan Stilgenbauer, MD³

¹ Department of Internal Medicine III, Division of CLL, Ulm University, Ulm, Germany

² Internal Medicine, Division of Hematology, German Military Hospital Ulm, Ulm, Germany

³ Department of Internal Medicine III, Division of CLL, Ulm University, Ulm, Germany

⁴ Department of Internal Medicine III, Division of CLL, Ulm University, Ulm, Germany

⁵ Division of CLL, Department of Internal Medicine III, University of Ulm, Ulm, Germany

⁶ Faculty of Medicine and University Hospital Cologne, Department I of Internal Medicine, Center for Integrated Oncology Aachen Bonn Cologne Duesseldorf; German CLL Study Group, University of Cologne, Cologne, Germany

⁷ Study Centrum Unter Ems, Practice for Oncology and Hematology, Leer, Germany

⁸ Outpatient Clinic, Landshut, Germany

⁹ Onkologische Schwerpunktpraxis Erlangen, Erlangen, Germany

¹⁰ Medicinum, Hildesheim, Germany

¹¹ Hämatologisch-onkologische Schwerpunktpraxis Würzburg, Würzburg, Germany

¹² Brüderkrankenhaus St. Josef, Paderborn, Germany

¹³ Praxis für internistische Onkologie und Hämatologie (PIOH), Frechen, Germany

¹⁴ University of Cologne, Cologne, Germany

¹⁵ Faculty of Medicine and Cologne University Hospital, Department I of Internal Medicine, Center for Integrated Oncology Aachen Bonn Cologne Duesseldorf, University of Cologne, Cologne, Germany, Cologne, Germany

Background: Watch and wait is standard of care in patients with early stage chronic lymphocytic leukemia (CLL). In the CLL12 trial, 515 stage Binet-A patients were risk stratified and randomized 1:1 to ibrutinib (ibr, n=182) or placebo (pcb, n=181) when assigned to (very) high or intermediate risk, while low risk patients were only observed (w&w, n=152). Treatment with ibr was associated with longer progression-free survival (PFS) (event defined as progression or death) and event-free survival (EFS) (event defined as death, symptomatic progression or initiation of CLL treatment) but not overall survival (OS) when compared to pcb (Langerbeins et al. EHA 2023). However, it is unclear if specific subgroups defined by genetic markers may derive particular benefit from early ibr treatment.

Methods: Genetic markers were analyzed in all 515 patients at study entry. Genomic aberrations were assessed by FISH, IGHV mutational status by sequencing with a threshold of 98% homology and gene mutations via targeted NGS for *TP53*, *FBXW7*, *NOTCH1*, *SF3B1*, *NRAS*, *KRAS*, *BRAF*, *BIRC3*, *MYD88*, *NFKB1E*, *EGR2* and *XPO1*.

Results: The prevalence of genomic aberrations and gene mutations is shown in the table 1.

At a median follow up of 69.3 months, there were 166 events for EFS and 32 for OS respectively. EFS was shorter with del(17p) (compared to del(13q): Hazard ratio (HR) 2.89, 95%CI 1.14-7.37, p<0.05), del(11q) (HR 4.39, 95%CI 2.48-7.76, p<0.001); +(12) (HR 1.78, 95%CI 1.01-3.13, p<0.05) in the pcb arm, while with ibr only del(17p) (HR 5.07, 95%CI 1.70-15.17 p<0.01) was associated with shorter EFS. IGHV mutation status had an impact on EFS with pcb (U-IGHV vs. M-IGHV, HR 4.44, 95%CI 2.88-6.85, p<0.001) but not with ibr (HR 1.52, 95%CI 0.81-2.85, p=0.19).

In the pcb arm, mutations in *NOTCH1* (HR 2.26, 95%CI 1.35-3.76, p<0.01), *NRAS/KRAS/BRAF*, (HR 5.38, 95%CI 1.92-15.03, p<0.01) and *NFKB1E* (HR 4.12, 95%CI 1.97-8.64, p<0.001) but not *TP53* (HR 1.24, 95%CI 0.57-2.68, p=0.59) were significantly associated with a shorter EFS. In contrast, with ibr treatment, only *TP53* (HR 2.88, 95%CI 1.31-6.32, p<0.01) and *NFKB1E* (HR 2.45, 95%CI 1.03-5.87, p=0.04) were associated with shorter EFS. Notably, in the full trial population (i.e. including the w&w

cohort) *TP53* mutations were associated with shorter EFS only when combined with U-IGHV (HR 2.37, 95%CI 1.22-4.63, $p < 0.05$) but not with M-IGHV (HR 0.53, 95%CI 0.26-1.10, $p = 0.09$).

In the w&w cohort high risk markers were rare and only +(12) (compared to del(13q)(HR 4.66, 95%CI 1.4-15.51, $p < 0.05$) and mutations in *TP53* (HR 4.88, 95%CI 1.49-16.04, $p < 0.01$), *SF3B1* (HR 5.01, 95%CI 1.53-16.45, $p < 0.01$), *BIRC3* (HR 3.43, 95%CI 1.05-11.23, $p < 0.05$) and *NFKB1E* (HR 12.58, 95%CI 3.68-42.99, $p < 0.001$) were significantly associated with shorter EFS.

Significant EFS benefit from ibr as compared to pcb with HR <0.2 was observed in subgroups with U-IGHV (HR 0.18, 95%CI 0.1-0.3, $p < 0.001$); del(11q) (HR 0.10, 95%CI 0.04-0.29, $p < 0.001$) and cases with mutations in *NOTCH1* (HR 0.18, 95%CI 0.06-0.55, $p < 0.01$) and *NFKB1E* (HR 0.15, 95%CI 0.04-0.53, $p < 0.01$), while no significant benefit was observed with del(17p) (HR 0.68, 95%CI 0.16-2.85, $p = 0.59$) and mutated *TP53* (HR 0.69, 95%CI 0.25-1.92, $p = 0.48$, figure 1). Regarding OS none of the subgroups defined by genetic markers derived significant benefit from ibr as compared to pcb.

In multivariable analysis for EFS including treatment arms, clinical disease characteristics and genetic markers as variables, ibr treatment was an independent favorable factor (HR 0.25, 95%CI 0.16-0.37, $p < 0.001$), while U-IGHV (HR 3.38, 95%CI 2.29-4.98 $p < 0.001$), del(17p) (HR 3.53, 95%CI 1.76-7.06, $p < 0.001$), +(12) (HR 1.58, 95%CI 1.01-2.45 $p < 0.05$) and mutated *NFKB1E* (HR 2.22, 95%CI 1.23-4.01, $p < 0.01$) were independent adverse prognostic factors.

Conclusion: In addition to the well-known prognostic factors, also mutated *SF3B1*, *NFKB1E* and *BIRC3* are associated with shorter EFS in low risk early stage CLL. While some genetic subgroups derived particular EFS benefit from ibr, patients with high-risk *TP53* aberration and/or del(17p) did not. In summary, the CLL12 trial fails to demonstrate survival superiority by early ibr treatment, including genetic subgroups and w&w remains the standard of care for all patients with Binet stage A CLL.

Disclosures Tausch: Abbvie: Consultancy, Honoraria, Other: Travel Support, Research Funding, Speakers Bureau; Roche: Consultancy, Honoraria, Research Funding, Speakers Bureau; Janssen-Cilag: Consultancy, Honoraria, Other: travel support, Speakers Bureau; AstraZeneca: Consultancy, Honoraria, Other: travel support, Speakers Bureau; BeiGene: Consultancy, Other: Travel support, Speakers Bureau. **Yosifov:** Bayer: Current equity holder in publicly-traded company; Roche: Current equity holder in publicly-traded company. **Schneider:** BeiGene: Other: travel support; AstraZeneca: Consultancy, Honoraria, Speakers Bureau; Abbvie: Honoraria, Speakers Bureau; Janssen Cilag: Consultancy. **Fink:** AstraZeneca: Consultancy, Honoraria, Research Funding; Abbvie: Other: travel support. **Eichhorst:** AstraZeneca: Consultancy, Honoraria, Research Funding, Speakers Bureau; BeiGene: Consultancy, Honoraria, Research Funding, Speakers Bureau; Gilead: Consultancy, Research Funding; Janssen: Consultancy, Research Funding, Speakers Bureau; Lilly: Consultancy, Speakers Bureau; MSD: Consultancy, Honoraria, Speakers Bureau; F. Hoffmann-La Roche Ltd: Honoraria, Research Funding, Speakers Bureau; Abbvie: Consultancy, Honoraria, Research Funding, Speakers Bureau. **Fischer:** Abbvie: Honoraria, Other: TRavel support; AstraZeneca: Consultancy; Roche: Honoraria, Other: Travel Support. **Hallek:** Abbvie: Consultancy, Honoraria, Research Funding; Roche: Consultancy, Honoraria, Research Funding; BeiGene: Consultancy, Honoraria, Research Funding; Gilead: Consultancy, Honoraria, Research Funding; AstraZeneca: Consultancy, Honoraria, Research Funding; Janssen: Consultancy, Honoraria, Research Funding. **Langerbeins:** Abbvie: Honoraria, Other: travel support; Janssen: Honoraria, Other: travel support, Research Funding; Beigene: Honoraria, Other: travel support; AstraZeneca: Honoraria, Other: travel support. **Stilgenbauer:** Amgen: Consultancy, Honoraria, Other: travel support, Research Funding; Abbvie: Consultancy, Honoraria, Other: travel support, Research Funding; Novartis: Consultancy, Honoraria, Other: travel support, Research Funding; Janssen: Consultancy, Honoraria, Other: travel support, Research Funding; Sunesis: Consultancy, Honoraria, Other: travel support, Research Funding; Gilead: Consultancy, Honoraria, Other: travel support, Research Funding; Celgene: Consultancy, Honoraria, Other: travel support, Research Funding; AstraZeneca: Consultancy, Honoraria, Other: travel support, Research Funding; Roche: Consultancy, Honoraria, Other: travel support, Research Funding; GSK: Consultancy, Honoraria, Other: travel support, Research Funding.

Table 1: Prevalence of genomic aberrations and gene mutations

Aberrations and mutations [%]	all n=515	ibr n=182	pcb n=181	w+w n=152
U-IGHV	28.8	38.7	38.7	5.3
del (17p)	2.5	3.3	3.9	0.0
del (11q)	7.8	11.5	10.5	0.0
+(12)	10.9	13.2	15.5	2.6
no abnormalities	18.1	19.8	16.6	17.8
del (13q)	60.8	52.2	53.6	79.6
NOTCH1	7.6	8.2	12.7	0.7
SF3B1	7.4	7.7	11.0	2.6
TP53	6.8	9.9	7.2	2.6
BIRC3	5.2	4.4	7.7	3.3
NFKB1E	4.9	7.7	4.4	2.0
MYD88	3.3	3.3	3.3	3.3
FBXW7	2.9	3.8	3.9	0.7
XPO1	1.9	1.1	4.4	0.0
NRAS/KRAS/BRAF	1.4	1.1	2.8	0.0
EGR2	0.6	1.6	0.0	0.0

Figure 1: Event free survival TP53




Figure 1

<https://doi.org/10.1182/blood-2023-180558>

Downloaded from http://ashpublications.net/blood/article-pdf/142/Supplement_1/199/2203475/blood-4803-main.pdf by guest on 16 May 2024